CJC-1295 (No DAC), also known as Modified GRF (1-29), is a synthetic 29-amino-acid analogue of growth-hormone-releasing hormone (GHRH), supplied as a lyophilised research material. It is used in laboratory studies of GHRH-receptor signalling and peptide structure.
This material is not supplied as a medicine, treatment, supplement or consumer product. It is not for human or veterinary use, consumption or administration, and is not intended to diagnose, treat, cure or prevent any disease.
Compound overview
Research context
The No DAC peptide contains substitutions at positions 2, 8, 15 and 27 of GRF (1-29). It lacks the albumin-binding drug affinity complex (DAC) modification. No DAC and DAC materials are distinct chemical entities; findings from studies of the DAC form should not be assumed to apply to this product.
The formula and molecular mass above describe the reference peptide free base. Counterions, water content and formulation can affect the supplied material. Reference information does not establish a vial’s identity, purity or suitability for a particular experiment; consult the matching batch documentation.
Batch documentation
Independent analytical documentation is published where available for specific batches and variations. A result indicator appears only when a published record is available. Match the compound, vial size and batch identifier to the corresponding report before relying on any result.
Supply and laboratory handling
- Supplied in the vial size selected above.
- Provided as a lyophilised research material.
- Keep the vial sealed and protected from moisture, heat and direct light.
- Use suitable laboratory controls and independently verify identity and concentration for the intended experimental model.
Frequently asked questions
What is CJC-1295 (No DAC)?
A modified GHRH fragment, also called Modified GRF (1-29), supplied here for laboratory research.
How does No DAC differ from With DAC?
The No DAC form has no albumin-binding DAC modification. Use documentation specific to the selected form rather than treating the two as interchangeable.
What does the reference sequence describe?
The 29-residue, C-terminally amidated reference peptide. D-Ala identifies the D-alanine residue at position 2; the full sequence is listed in the compound overview.
Which vial sizes are available?
Current selectable vial sizes and availability are shown above. These controls update automatically as variations change.
Are laboratory results available?
A shield appears beside a variation only when a published result is available. No indicator means that no product-specific result is currently displayed for that variation. Check the COA tab for available records.
How should the material be stored?
See the Storage Guidelines tab for the current handling guidance for sealed lyophilised material and reconstituted solution. Follow any batch-specific instructions supplied with the material.
Information reviewed 27 September 2026. Reference: FDA scientific review of CJC-1295-related substances (chemical identification and distinction between No DAC and DAC forms).
